SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TOANTI-TNF THERAPY: 52-WEEK RESULTS FROM TWO INTERNATIONAL PHASE 3 TRIALS

被引：0

作者：

Deodhar, Atul ^{[1
]}

Baeten, Dominique ^{[2
]}

Blanco, Ricardo ^{[3
]}

Sieper, Joachim ^{[4
]}

Martin, Ruvie ^{[5
]}

Porter, Brian ^{[5
]}

Richards, Hanno ^{[6
]}

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[2] Univ Amsterdam, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands

[3] Hosp Marques Valdecilla, Madrid, Spain

[4] Charite Univ Med Berlin, Berlin, Germany

[5] Novartis Pharmaceut, New York, NY USA

[6] Novartis Pharma AG, Basel, Switzerland

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3287369

引用

页码：137 / 138

页数：2

共 42 条